NeuroNEXT

Goodman AD, Fedler JK, Yankey J, Klingner EA, Ecklund DJ, Goebel CV, Bernel RA, Chase M, Coffey CS, Klawiter EC, Naismith RT, Fox RJ on behalf of the SPRINT-MS Investigators.

Response to Ibudilast treatment according to progressive multiple sclerosis disease phenotype

PubMed: PMC7818089

Robert A Bermel, Janel K Fedler, Peter Kaiser, Cindy Novalis, Jeff Schneebaum, Elizabeth A Klingner, Dawn Williams, Jon W Yankey, Dixie J Ecklund, Marianne Chase, Robert T Naismith, Eric C Klawiter, Andrew D Goodman, Christopher S Coffey and Robert J Fox

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

PubMed: 33054533

Merit Cudkowicz, MD, MSc; Marianne K. Chase, BA; Christopher S. Coffey, PhD; Dixie J. Ecklund, RN, MSN, MBA;
Brenda J. Thornell, BA; Codrin Lungu, MD; Katy Mahoney, BS; Laurie Gutmann, MD; JeremyM. Shefner,MD, PhD;
Kevin J. Staley, MD; Michael Bosch, RN; Eric Foster, PhD; Jeffrey D. Long, PhD; Emine O. Bayman, PhD;
James Torner, PhD; Jon Yankey, MS; Richard Peters, BS; Trevis Huff, BSE; Robin A. Conwit, MD;
and the NeuroNEXT Clinical Study Sites

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials

PubMed: PMC7483960

Michael J. Brownstein, Neal G. Simon, Jeffrey D. Long, Jon Yankey, Hilda T. Maibach, Merit Cudkowicz, Christopher Coffey, Robin A. Conwit, Codrin Lungu, Karen E. Anderson, Steven M. Hersch, Dixie J. Ecklund, Eve M. Damiano, Debra E. Itzkowitz, Shifang Lu, Marianne K. Chase, Jeremy M. Shefner, Andrew McGarry, Brenda Thornell, Catherine Gladden, Michele Costigan, Padraig O’Suilleabhain, Frederick J. Marshall, Amy M. Chesire, Paul Deritis, Jamie L. Adams, Peter Hedera, Kelly Lowen, H. Diana Rosas, Amie L. Hiller, Joseph Quinn, Kellie Keith, Andrew P. Duker, Christina Gruenwald, Angela Molloy, Cara Jacob, Stewart Factor, Elaine Sperin, Danny Bega, Zsazsa R. Brown, Lauren C. Seeberger, Victor W. Sung, Melanie Benge, Sandra K. Kostyk, Allison M. Daley, Susan Perlman, Valerie Suski, Patricia Conlon, Matthew J. Barrett, Stephanie Lowenhaupt, Mark Quigg, Joel S. Perlmutter, Brenton A. Wright, Elaine Most, Guy J. Schwartz, Jessica Lamb, Rosalind S. Chuang, Carlos Singer, Karen Marder, Joyce A. Moran, John R. Singleton, Meghan Zorn, Paola V. Wall, Richard M. Dubinsky, Carolyn Gray and Carolyn Drazinic

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

PubMed: PMC7696926

Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AQ, Griffin JH, Zlokovic BV, the NeuroNEXT Clinical Trials Network NN104 Investigators

Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant Human Activated Protein C, in Combination with Tissue Plasminogen Activ…

PubMed:

Bartlett A, Kolb SJ, Kinglsey A, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnett BW, Werner K, Thangarajh M, Shieh PB, Finanger E, Coffey CS, Yankey JW, Cudkowicz ME, McGovern MM, McNeil ED, Arnold DW, Kissel JT, The NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.

Recruitment & Retention Program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

PubMed: PMC6072892

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund DJ, Klinger E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MK, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt D, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repobic P, Riler CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A for the NN102/SPRINT-MS Trial Investigators

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

PubMed: PMC6172944

Krosschell KJ, Bosch M, Nelson L, Duong T, Lowes LP, Alfano LN, Benjamin D, Carry TB, Devine G, Kelley C, Gadekan R, Malkus EC, Pasternak A, Provance-Orr S, Roemeiser-Logan L, Nicorici A, Trussell D, Young SD, Fetterman JR, Montes J, Powers PJ, Quinones R, Quigley J, Coffey CS, Yankey JW, Bartlett AW, Kissel JT, Kolb SJ, NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.

Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study

PubMed: 30223401

Kolb SJ, Coffey CS, Yankey JW, Korsschell KP, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Parsons J, Connolly A, Chiriboga CA, McDonald C, Burnette B, Werner W, Thangarajh M, Shieh P, Finanger E, Cudkowicz M, McGovern MM, McNeil DE, Finkel R, Iannacone ST, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes A, Bartlett AHM, Kissel JT the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators.

Natural History of Infantile-Onset Spinal Muscular Atrophy

PubMed: PMC5776712

Rutkove SB, Darras BT

NeuroNEXT is at your service

PubMed: